The Role of Medical Management for Acute Intravascular Hemolysis in Patients Supported on Axial Flow LVAD

Continuous flow left ventricular assist devices (LVADs) are used with good outcome. However, acute intravascular hemolysis due to thrombus in the pump remains a clinical challenge. We screened for LVAD-related intravascular hemolysis among 115 consecutive patients surviving HeartMateII implantation and investigated the role of medical therapy in resolving the hemolysis. Hemolytic events were identified in 7% of patients, 2–26 months after implant, manifested by peak lactate dehydrogenase (LDH) levels >6 times normal. With the institution of heparin and enhanced antiplatelet therapy, LDH levels receded rapidly reaching a stable trough level near baseline within 2 weeks with the resolution of clinical symptoms except in one patient who required additional therapy with tissue plasminogen activator (tPA). Complications included transient renal failure, one splenic infarct, and a cerebrovascular attack after tPA. The acute event of hemolysis resolved with medical therapy, and all were successfully discharged. However, recurrent hemolysis was common (6/8 patients over the next 1–7 months). At the end of follow-up, three patients were transplanted, one patient died refusing LVAD exchange for recurrent hemolysis, and 4 remained alive on LVAD support. Medical treatment with intensification of anticoagulation can be effective in resolving the acute hemolytic event. However, a definitive long-term strategy should be planned because the recurrence rate is high.

[1]  S. Russell,et al.  Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  N. Kapur,et al.  Management of HeartWare left ventricular assist device thrombosis using intracavitary thrombolytics. , 2011, The Journal of thoracic and cardiovascular surgery.

[3]  Nader Moazami,et al.  Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. , 2009, Journal of the American College of Cardiology.

[4]  T. Myers,et al.  Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  B. Reichart,et al.  Platelet activation markers in patients with heart assist device. , 2005, Artificial organs.

[6]  S. Kushwaha,et al.  Discontinuation of antithrombotic therapy for a year or more in patients with continuous-flow left ventricular assist devices. , 2010, Interactive cardiovascular and thoracic surgery.

[7]  Christoph Benk,et al.  Haemolysis in patients with ventricular assist devices: major differences between systems. , 2009, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  Joel D. Graham,et al.  Fibrinolytic Activation During Long-term Support With the Heartmate II Left Ventricular Assist Device , 2008, ASAIO journal.

[9]  W. Kop,et al.  Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices , 2009, Nature Clinical Practice Cardiovascular Medicine.

[10]  Andrew Boyle,et al.  Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. , 2009, The Journal of thoracic and cardiovascular surgery.

[11]  L. Dembo,et al.  Successful treatment of rotary pump thrombus with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  J. Oh,et al.  Echocardiographic Variables After Left Ventricular Assist Device Implantation Associated With Adverse Outcome , 2011, Circulation. Cardiovascular imaging.

[13]  L. Miller,et al.  Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. , 2008, The Journal of thoracic and cardiovascular surgery.

[14]  R. Hebbel,et al.  Activation of endothelial and coagulation systems in left ventricular assist device recipients. , 2009, The Annals of thoracic surgery.

[15]  D. Jennings,et al.  Assessment of long-term anticoagulation in patients with a continuous-flow left-ventricular assist device: a pilot study. , 2011, The Journal of thoracic and cardiovascular surgery.

[16]  Stefan Fischer,et al.  Thrombus formation in a HeartMate II left ventricular assist device. , 2008, The Journal of thoracic and cardiovascular surgery.

[17]  L. Stevenson,et al.  Third INTERMACS Annual Report: the evolution of destination therapy in the United States. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  S. Mohammad,et al.  Mitigation of device-associated thrombosis and thromboembolism using combinations of heparin and tirofiban. , 2006, The journal of extra-corporeal technology.

[19]  Klaus Affeld,et al.  The effect of surface roughness on activation of the coagulation system and platelet adhesion in rotary blood pumps. , 2007, Artificial organs.

[20]  C. Bhamidipati,et al.  Early thrombus in a HeartMate II left ventricular assist device: a potential cause of hemolysis and diagnostic dilemma. , 2010, The Journal of thoracic and cardiovascular surgery.

[21]  Joel D. Graham,et al.  Platelet Activation in Heart Failure Patients Supported by the HeartMate II Ventricular Assist Device , 2011, The International journal of artificial organs.

[22]  S. Russell,et al.  Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.

[23]  Markus J. Wilhelm,et al.  Treatment of Thrombus Formation Associated With the MicroMed DeBakey VAD Using Recombinant Tissue Plasminogen Activator , 2002, Circulation.

[24]  T. Schmitz-Rode,et al.  Consequences arising from elevated surface temperatures on human blood. , 2010, Artificial organs.

[25]  L. Dembo,et al.  Successful treatment of ventricular assist device associated ventricular thrombus with systemic tenecteplase. , 2008, Heart, lung & circulation.

[26]  Nir Uriel,et al.  Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. , 2012, Journal of the American College of Cardiology.

[27]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[28]  R. Delgado,et al.  A successful anticoagulation protocol for the first HeartMate II implantation in the United States. , 2005, Texas Heart Institute journal.